IELSG52, V.1.0

• Research type

  Research Study

• Full title

  Integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma

• IRAS ID

  335163

• Contact name

  Renata Walewska

• Contact email

  renata.walewska@uhd.nhs.uk

• Sponsor organisation

  International Extranodal Lymphoma Study Group

• Clinicaltrials.gov Identifier

  NCT05700149

• Clinicaltrials.gov Identifier

  ClinicalTrials.Gov Number, NCT05700149

• Duration of Study in the UK

  4 years, 0 months, 0 days

• Research summary

  Already existing and coded tumor biological material from the lymph node biopsy and personal health-related data of patients who have been diagnosed with NMZL will be collected retrospectively.The value of the expected results of the IELSG52 study are: (i) to inform on diagnosis and prognosis of NMZL; (ii) to allow selection of optimal therapy; and (iii) to provide a biology based framework on which to design and interpret clinical trials

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  24/SW/0056

• Date of REC Opinion

  16 Jul 2024

• REC opinion

  Further Information Favourable Opinion